Current concepts in normal and defective angiogenesis: Implications for systemic sclerosis

Current Rheumatology Reports

Volumn 9, Issue 2, 2007, Pages 173-179

  Mulligan Kehoe, Mary Jo ^b   Simons, Michael ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; AUTOANTIBODY;

ANGIOGENESIS; CELL LOSS; DNA MICROARRAY; ENDOTHELIUM CELL; FIBROSIS; HUMAN; NONHUMAN; REVIEW; SYSTEMIC SCLEROSIS; VASCULAR DISEASE; WOUND HEALING;

CONNECTIVE TISSUE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; SCLERODERMA, SYSTEMIC; WOUND HEALING;

EID: 34250661158     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-007-0013-2     Document Type: Review

References (59)

1. LeRoy EC: Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 1996, 22:675-694.
2. Wigley FM, Flavahan NA: Raynaud's phenomenon. Rheum Dis Clin North Am 1996, 22:765-781.
3. Cutolo M, Pizzorni C, Tuccio M, et al.: Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. Rheumatology (Oxford) 2004, 43:719-726.
4. Distler O, Distler JH, Scheid A, et al.: Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004, 95:109-116. Role of VEGF in Raynaud's phenomenon.
5. Gill M, Dias S, Hattori K, et al.: Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ Res 2001, 88:167-174.
6. Kuwana M, Okazaki Y, Yasuoka H, et al.: Defective vasculogenesis in systemic sclerosis. Lancet 2004, 364:603-610.
7. Del Papa N, Quirici N, Soligo D, et al.: Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum 2006, 54:2605-2615.
8. Kahaleh MB, Sherer GK, LeRoy EC: Endothelial injury in scleroderma. J Exp Med 1979, 149:1326-1335.
9. Youinou P, Revelen R, Bordron A: Is antiendothelial cell antibody the murder weapon in systemic sclerosis? Clin Exp Rheumatol 1999, 17:35-36.
10. Hill MB, Phipps JL, Cartwright RJ, et al.: Antibodies to membranes of endothelial cells and fibroblasts in scleroderma. Clin Exp Immunol 1996, 106:491-497.
11. Negi VS, Tripathy NK, Misra R, Nityanand S: Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol 1998, 25:462-466.
12. Garcia de la Pena-Lefebvre P, Chanseaud Y, Tamby MC, et al.: IgG reactivity with a 100-kDa tissue and endothelial cell antigen identified as topoisomerase 1 distinguishes between limited and diffuse systemic sclerosis patients. Clin Immunol 2004, 111:241-251.
13. Tamby MC, Chanseaud Y, Humbert M, et al.: Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax 2005, 60:765-772.
14. Wigley FM, Wise RA, Miller R, et al.: Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis. Arthritis Rheum 1992, 35:688-693.
15. Sgonc R, Gruschwitz MS, Dietrich H, et al.: Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996, 98:785-792.
16. Worda M, Sgonc R, Dietrich H, et al.: In vivo analysis of the apoptosis-inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorionallantoic membrane assay. Arthritis Rheum 2003, 48:2605-2614.
17. Bordron A, Dueymes M, Levy Y, et al.: The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest 1998, 101:2029-2035.
18. Casciola-Rosen LA, Anhalt G, Rosen A: Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994, 179:1317-1330.
19. Sercarz EE, Lehmann PV, Ametani A, et al.: Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 1993, 11:729-766.
20. Zhou Z, Menard HA: Autoantigenic posttranslational modifications of proteins: does it apply to rheumatoid arthritis? Curr Opin Rheumatol 2002, 14:250-253.
21. Izquierdo M, Grandien A, Criado LM, et al.: Blocked negative selection of developing T cells in mice expressing the baculovirus p35 caspase inhibitor. Embo J 1999, 18:156-166.
22. Andrade F, Roy S, Nicholson D, et al.: Granzyme B directly and efficiently cleaves several downstream caspase substrates: implications for CTL-induced apoptosis. Immunity 1998, 8:451-460.
23. Casciola-Rosen L, Andrade F, Ulanet D, et al.: Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med 1999, 190:815-826.
24. Schachna L, Wigley FM, Morris S, et al.: Recognition of Granzyme B-generated autoantigen fragments in scleroderma patients with ischemic digital loss. Arthritis Rheum 2002, 46:1873-1884.
25. Ahmed SS, Tan FK, Arnett FC, et al.: Induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells by scleroderma sera containing anti-endothelial cell antibodies. Arthritis Rheum 2006, 54:2250-2262.
26. Tan FK, Arnett FC, Reveille JD, et al.: Autoantibodies to fibrillin 1 in systemic sclerosis: ethnic differences in antigen recognition and lack of correlation with specific clinical features or HLA alleles. Arthritis Rheum 2000, 43:2464-2471.
27. Baroni SS, Santillo M, Bevilacqua F, et al.: Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006, 354:2667-2676. Demonstration of an ECM function for granzyme B.
28. Edelberg JM, Lee SH, Kaur M, et al.: Platelet-derived growth factor-AB limits the extent of myocardial infarction in a rat model: feasibility of restoring impaired angiogenic capacity in the aging heart. Circulation 2002, 105:608-613.
29. Buzza MS, Zamurs L, Sun J, et al.: Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin, and laminin. J Biol Chem 2005, 280:23549-23558.
30. Sasaki T, Larsson H, Tisi D, et al.: Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity. J Mol Biol 2000, 301:1179-1190.
31. Maeshima Y, Sudhakar A, Lively JC, et al.: Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002, 295:140-143.
32. Kamphaus GD, Colorado PC, Panka DJ, et al.: Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 2000, 275:1209-1215.
33. Cao Y, Ji RW, Davidson D, et al.: Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J Biol Chem 1996, 271:29461-29467.
34. Ferrara N, Clapp C, Weiner R: The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology 1991, 129:896-900.
35. Staton CA, Lewis CE: Angiogenesis inhibitors found within the haemostasis pathway. J Cell Mol Med 2005, 9:286-302.
36. Hebbar M, Peyrat JP, Hornez L, et al.: Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum 2000, 43:889-893.
37. Giusti B, Serrati S, Margheri F, et al.: The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. Arthritis Rheum 2005, 52:3618-3628. Provides evidence of an imbalance of pro- versus antiangiogenic factors in scleroderma microvascular cells.
38. Del Rosso A, Distler O, Milia AF, et al.: Increased circulating levels of tissue kallikrein in systemic sclerosis correlate with microvascular involvement. Ann Rheum Dis 2005, 64:382-387.
39. Bhoola KD, Figueroa CD, Worthy K: Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992, 44:1-80.
40. Plendl J, Snyman C, Naidoo S, et al.: Expression of tissue kallikrein and kinin receptors in angiogenic microvascular endothelial cells. Biol Chem 2000, 381:1103-1115.
41. Emanueli C, Madeddu P: Targeting kinin receptors for the treatment of tissue ischaemia. Trends Pharmacol Sci 2001, 22:478-484.
42. Giusti B, Fibbi G, Margheri F, et al.: A model of antiangiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients. Arthritis Res Ther 2006, 8:R115. Microarray analysis of scleroderma gene expression and categorization of the genes into functional groups based on gene ontology.
43. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J: Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999, 285:1926-1928.
44. Staton CA, Brown NJ, Rodgers GR, et al.: Alphastatin, a 24-amino acid fragment of human fibrinogen, is a potent new inhibitor of activated endothelial cells in vitro and in vivo. Blood 2004, 103:601-606.
45. Colorado PC, Torre A, Kamphaus G, et al.: Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res 2000, 60:2520-2526.
46. Beecken WD, Engl T, Ringel EM, et al.: An endogenous inhibitor of angiogenesis derived from a transitional cell carcinoma: clipped beta2-glycoprotein-I. Ann Surg Oncol 2006, 13:1241-1251.
47. Davies Cde L, Melder RJ, Munn LL, et al.: Decorin inhibits endothelial migration and tube-like structure formation: role of thrombospondin-1. Microvasc Res 2001, 62:26-42.
48. O'Reilly MS, Boehm T, Shing Y, et al.: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
49. Albig AR, Schiemann WP: Fibulin-5 antagonizes vascular endothelial growth factor (VEGF) signaling and angiogenic sprouting bv endothelial cells. DNA Cell Biol 2004, 23:367-379.
50. Dawson DW, Volpert OV, Gillis P, et al.: Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999, 285:245-248.
51. Maione TE, Gray GS, Petro J, et al.: Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990, 247:77-79.
52. Mulligan-Kehoe MJ, Wagner R, Wieland C, Powell R: A truncated plasminogen activator inhibitor-1 protein induces and inhibits angiostatin (kringles 1-3), a plasminogen cleavage product. J Biol Chem 2001, 276:8588-8596.
53. Kim JS, Chang JH, Yu HK, et al.: Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a). J Biol Chem 2003, 278:29000-29008.
54. Tolsma SS, Volpert OV, Good DJ, et al.: Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 1993, 122:497-511.
55. Stetler-Stevenson WG, Seo DW: TIMP-2: an endogenous inhibitor of angiogenesis. Trends Mol Med 2005, 11:97-103.
56. Whitfield ML, Finlay DR, Murray JI, et al.: Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 2003, 100:12319-12324.
57. Leask A, Abraham DJ, Finlay DR, et al.: Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts. Arthritis Rheum 2002, 46:1857-1865.
58. Lawrence A, Khanna D, Misra R, Aggarwal A: Increased expression of basic fibroblast growth factor in skin of patients with systemic sclerosis. Dermatol Online J 2006, 12:2.
59. D'Alessio S, Fibbi G, Cinelli M, et al.: Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum 2004, 50:3275-3285.